The FDA-approved anti-amyloid-β monoclonal antibodies for the treatment of Alzheimer’s disease: a systematic review and meta-analysis of randomized controlled trials

BACKGROUND: Alzheimer’s disease (AD) is a worldwide public health problem and is difficult to cure. Drugs aimed at slowing the progression of the disease have been developed, with the Food and Drug Administration (FDA) granting accelerated approval for aducanumab on June 21, 2021 and a new accelerat...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Wenxue, Ji, Yi, Wang, Zilan, Wu, Xiaoxiao, Li, Jiaxuan, Gu, Feng, Chen, Zhouqing, Wang, Zhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10683264/
https://www.ncbi.nlm.nih.gov/pubmed/38017568
http://dx.doi.org/10.1186/s40001-023-01512-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10683264/
https://www.ncbi.nlm.nih.gov/pubmed/38017568
http://dx.doi.org/10.1186/s40001-023-01512-w

Ejemplares similares